Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer
New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial
Pharmaceutical Investing Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities
Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
